Generation Bio is a genetic medicines company creating gene therapy utilizing its non-viral gene therapy platform. It combines three technologies: a cell-targeted lipid nanoparticle delivery system (ctLNP), a closed-ended DNA construct (ceDNA), and a high-capacity capsid-free biologics manufacturing process. In addition to its lead liver-targeted programs in hemophilia A and phenylketonuria (PKU), Generation Bio develops gene therapies for patients with diseases of skeletal muscle and the eye.